Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
AssigneeImmunomedics, Inc.
InventorDavid M. Goldenberg
Life of this patent
Estimating the term…
Abstract
Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.
Claims24
A method for detecting the location of multidrug resistant (MDR) tumor cells MDMDR HIV-infected cells or MDR infectious agents in a mammal having a multidrug resistant disease caused by a tumor or infectious agent, said method comprising the steps of:
- (a) parentsrally injecting the mammal with an antibody composite comprising (1) at least one antibody component that binds a first epitope of a multidrug transporter protein, and (2) at least one antibody component that binds a first epitope of an antigen that is associated with the tumor or the infectious agent, wherein said antibody composite is conjugated with a biotin-binding molecule or with biotin;
- (b) parenterally injecting a clearing composition comprised of:
- (i) biotin, when said antibody composite is conjugated with a biotin-binding molecule, or
- (ii) a biotin-binding molecule, when said antibody composite is conjugated with biotin,
- and allowing said clearing composition to substantially clear said antibody composite from sites that do not contain MDR tumor cells, MDR HIV-infected cells or MDR infectious agents;
- and
- (c) parenterally injecting a diagnostic composition comprised of:
- (i) biotin, when said antibody composite is conjugated with a biotin-binding molecule, or
- (ii) a biotin-binding molecule, when said antibody composite is conjugated with biotin,
- and a diagnostic agent which is conjugated with said biotin or said biotin-binding molecule.
A method for detecting the location of multidrug resistant (MDR) tumor cells, MDR HIV-infected cells or MDR infectious agents in a mammal having a multidrug resistant disease caused by a tumor or infectious agent, said method comprising the steps of:
- (a) parenterally injecting the mammal with a polyspecific immunoconjugate that comprises (1) at least one antibody component that binds with a first epitope of a multidrug transporter protein, (2) at least one antibody component that binds with a first epitope of an antigen that is associated with the tumor or infectious agent, and (3) a diagnostic agent;
- and
- (b) scanning said mammal with a detector to locate the site or sites of uptake of said polyspecific immunoconjugate.
A method for detecting the location of multidrug resistant (MDR) tumor cells, MDR HIV-infected cells or MDR infectious agents in a subject having a multidrug resistant disease caused by a tumor or infectious agent, said method comprising the steps of:
- (a) parenterally injecting the subject with a polyspecific immunoconjugate comprising (1) at least one antibody component that binds with a first epitope of a multidrug transporter protein, (2) at least one antibody component that binds with a first epitope of an antigen that is associated with a tumor or infectious agent, and (3) a diagnostic agent;
- (b) surgically exposing or endoscopically accessing the interior of the body cavity of said subject;
- and
- (c) scanning said interior body cavity with a detection probe to detect the sites of accretion of said polyspecific immunoconjugate.
Dependencies are inferred from the claim text.